Articles

Ixazomib Monotherapy in RRMM Patients with Severe Renal Impairment or Those Requiring Hemodialysis
ASH 2015 – Multiple Myeloma
A pharmacokinetic and safety study of ixazomib in patients with severe renal impairment or end-stage renal disease requiring hemodialysis demonstrated that this patient subgroup requires dose modification of ixazomib due to a 38% higher, unbound systemic exposure. Administration of ixazomib may be administered without regard to the timing of dialysis. Read More ›
Management of Infusion-Related Reactions Associated with Daratumumab Monotherapy in RRMM
ASH 2015 – Multiple Myeloma
Researchers presented data relating to the management of infusion-related reactions (IRRs) associated with single-agent daratumumab treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the open-label, multicenter, phase 2 Sirius study. Read More ›
Ixazomib plus Panobinostat and Dexamethasone in Heavily Pretreated Patients with RRMM
ASH 2015 – Multiple Myeloma
Investigators propose moving to a phase 2 evaluation after using a new treatment regimen that was well-tolerated in patients with progressive disease consisting of panobinostat at 20 mg 3 times a week every other week to ixazomib at target 4 mg weekly, 3 weeks on, 1 week off, with dexamethasone 20 mg on the day of and after ixazomib. Read More ›
Patient Preferences on Treatment Attributes in MM
ASH 2015 – Multiple Myeloma
Researchers reported results of an online survey that examined the preferences of patients with multiple myeloma (MM) on route of administration and individual treatment-related adverse events. Read More ›

Page 128 of 147


© Amplity, Inc. All Rights Reserved. Privacy Policy